Figure 4.
Humoral and cellular immune response rate according to lymphocyte subpopulations and administered therapy. (A) In patients undergoing treatment with anti-CD20 therapy (n = 40), the influence of this monoclonal antibody's association with chemotherapy in the lymphocyte subpopulations and in the humoral or cellular response to the vaccine was determined. Abnormal values were considered as follows: CD19, >0.10 × 109/L; CD3, >0.7 × 109/L; CD4, 0.3 × 109/L; CD8, 0.2 × 109/L; and lymphopenia, 1.0 × 109/L. (B) In allo-SCT patients (n = 59), the influence of treatment with immunosuppressive agents or target therapy in the lymphocyte subpopulations and in the humoral or cellular response to the vaccine was determined.